NASDAQ: MNOV
Medicinova Inc Stock Forecast, Predictions & Price Target

Analyst price target for MNOV

Based on 2 analysts offering 12 month price targets for Medicinova Inc

Min Forecast
$5.00+293.7%
Avg Forecast
$7.00+451.18%
Max Forecast
$9.00+608.66%

Should I buy or sell MNOV stock?

Based on 2 analysts offering ratings for Medicinova Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MNOV stock forecasts and price targets.

MNOV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-16
lockedlocked$00.00+00.00%2025-04-09

1 of 1

Forecast return on equity

Is MNOV forecast to generate an efficient return?

Company
-28%
Industry
27.61%
Market
56.19%
MNOV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MNOV forecast to generate an efficient return on assets?

Company
-26.66%
Industry
10.53%
MNOV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MNOV earnings per share forecast

What is MNOV's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.27
Avg 2 year Forecast
-$0.29

MNOV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNOV$1.27$7.00+451.18%Strong Buy
QNCX$1.36$7.00+414.71%Strong Buy
ANRO$2.27$7.00+208.37%Buy
CLSD$0.79$4.75+501.27%Strong Buy
ANEB$1.55$3.00+93.55%Strong Buy

Medicinova Stock Forecast FAQ

Is Medicinova Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MNOV) stock is to Strong Buy MNOV stock.

Out of 2 analysts, 2 (100%) are recommending MNOV as a Strong Buy, 0 (0%) are recommending MNOV as a Buy, 0 (0%) are recommending MNOV as a Hold, 0 (0%) are recommending MNOV as a Sell, and 0 (0%) are recommending MNOV as a Strong Sell.

If you're new to stock investing, here's how to buy Medicinova stock.

What is MNOV's earnings growth forecast for 2025-2026?

(NASDAQ: MNOV) Medicinova's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.19%.

Medicinova's earnings in 2025 is -$11,159,151.On average, 2 Wall Street analysts forecast MNOV's earnings for 2025 to be -$13,242,486, with the lowest MNOV earnings forecast at -$14,713,874, and the highest MNOV earnings forecast at -$11,771,099.

In 2026, MNOV is forecast to generate -$13,978,180 in earnings, with the lowest earnings forecast at -$16,185,261 and the highest earnings forecast at -$11,771,099.

What is MNOV's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: MNOV) forecast ROE is -28%, which is considered weak.

What is MNOV's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MNOV price target, the average MNOV price target is $7.00, with the highest MNOV stock price forecast at $9.00 and the lowest MNOV stock price forecast at $5.00.

On average, Wall Street analysts predict that Medicinova's share price could reach $7.00 by Jun 16, 2026. The average Medicinova stock price prediction forecasts a potential upside of 451.18% from the current MNOV share price of $1.27.

What is MNOV's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: MNOV) Medicinova's current Earnings Per Share (EPS) is -$0.23. On average, analysts forecast that MNOV's EPS will be -$0.27 for 2025, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at -$0.24. In 2026, MNOV's EPS is forecast to hit -$0.29 (min: -$0.33, max: -$0.24).

What is MNOV's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: MNOV) forecast ROA is -26.66%, which is lower than the forecast US Biotechnology industry average of 10.53%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.